In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models

Planta Medica

Volumn 70, Issue 7, 2004, Pages 680-682

  Gobbi, Marco ^a   Moia, Manuela ^a   Funicello, Marcella ^a   Riva, Antonella ^b   Morazzoni, Paolo ^b   Mennini, Tiziana ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b INDENA S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DICYCLOHEXYLAMMONIUM; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NEUROKININ 1 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA CELL; BLOOD; CHEMICAL INTERACTION; CONCENTRATION RESPONSE; DEPRESSION; DRUG BINDING; DRUG INHIBITION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MEASUREMENT; NONHUMAN; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BICYCLO COMPOUNDS; CYCLOHEXYLAMINES; FEMALE; HUMANS; HYPERICUM; INHIBITORY CONCENTRATION 50; INTERLEUKIN-6; MALE; MODELS, ANIMAL; MODELS, BIOLOGICAL; PHLOROGLUCINOL; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, INBRED STRAINS; TERPENES;

HYPERICUM; HYPERICUM PERFORATUM;

EID: 3543013806     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-827194     Document Type: Article

References (22)

1. Linde K, Mulrow CD. St John's wort for depression. Cochrane Database Syst Rev, 2000 CD000448
2. Greeson JM, Sanford B, Monti DA. St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 2001; 153: 402-14
3. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997; 30 (Suppl 2): 129-34
4. Butterweck V, Jurgenliemk G, Nahrstedt A, Winterhoff H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Medica 2000; 66: 3-6
5. Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sciences 2003; 73: 627-39
6. Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Medica 1998; 64:291-4
7. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Muller WE. Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sciences 1998; 63: 499-510
8. Gambarana C, Tolu PL, Masi F, Rinaldi M, Giachetti D, Morazzoni P et al. A study of the antidepressant activity of Hypericum perforatum on animal models. Pharmacopsychiatry 2001; 34 (Suppl 1): S42-4
9. Cervo L, Rozio M, Ekalle-Soppo CB, Guiso G, Morazzoni P, Caccia S. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology 2002; 164: 423-8
10. Gobbi M, Dalla Valle F, Ciapparelli C, Diomede L, Morazzoni P, Verotta L et al. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn-Schmiedebergs Archives of Pharmacology 1999; 360: 262-9
11. Gobbi M, Mennini T. Is St John's wort a 'Prozac-like' herbal antidepressant? Trends in Pharmacological Sciences 2001; 22: 557-9
12. Butterweck V, Nahrstedt A, Evans J, Hufeisen S, Rauser L, Savage J et al. In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. Psychopharmacology 2002; 162: 193-202
13. Butterweck V, Winterhoff H, Herkenham M. St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol Psychiatry 2001; 6: 547-64
14. Fiebich BL, Hollig A, Lieb K. Inhibition of substance P-induced cytokine synthesis by St. John's wort extracts. Pharmacopsychiatry 2001; 34 (Suppl. 1): S26-8
15. Stout SC, Owens MJ, Nemeroff CB. Neurokinin(1) receptor antagonists as potential antidepressants. Annual Review of Pharmacology and Toxicology 2001; 41: 877-906
16. Dantzer R, Wollman EE, Yirmiya R. Cytokines and depression: an update. Brain, Behaviour and Immunology 2002; 16: 501-2
17. Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996; 17: 64-102
18. Thiele B, Brink I, Ploch M. Modulation of cytokine expression by Hypericum extract. Journal of Geriatric Psychiatry and Neurology 1994; 7 (Suppl 1): S60-2
19. Biber A, Fischer H, Romer A, Chatterjee SS. Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998; 31 (Suppl 1): 36-43
20. Calapai G, Crupi A, Firenzuoli F, Inferrera G, Ciliberto G, Parisi A et al. Interleukin-6 involvement in antidepressant action of Hypericum perforatum. Pharmacopsychiatry 2001; 34 (Suppl 1): S8-10
21. Verotta L, Appendino G, Belloro E, Bianchi F, Sterner O, Lovati M et al. Synthesis and biological evaluation of hyperforin analogues. Part I. Modification of the enolized cyclohexanedione moiety. J Nat Prod 2002; 65: 433-8
22. Palma C, Nardelli F, Manzini S. Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1 receptor antagonists. European Journal of Pharmacology 1999; 374: 435-43